Get in touch
The RNTreg OUS registry had its official opening on June 23, 2025.
Our research group is pleased to announce that we have had results from a phase 0-trial on AB001, a novel PSMA-targeted radioligand labeled with the α-emitter 212Pb, accepted for publication in the Journal of Nuclear Medicine. The study explores the use of γ-camera imaging to assess biodistribution and uptake of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC).
The study was conducted at Oslo University Hospital, and sponsored by ARTBIO. The publication was a result of an excellent multidisiplinary collaboration, and especially the joint first authors Kjetil Berner (Department of Oncology) and Eivor Hernes (Department of Nuclear Medicine), together with Monika Kvassheim and senior author Caroline Stokke (our group) played key roles. Group members Simen Rykkje Grønningsæter and Lars Tore Gyland Mikalsen also gave valuable contributions. The work showed that AB001 can be safely administered and imaged at a microdose of only 10 MBq, and successfully demonstrated metastatic targeting. The findings offer valuable insights into the biodistribution and clearance of 212Pb-labeled radioligands, paving the way for further clinical development in targeted alpha therapy.
Link to the (Open Acces) publication ahead of print
The Section for Nuclear Medicine Physics at Oslo University Hospital (OUS) is offering a full-time temporary position for a medical physicist.
The Theragnostic Imaging group has received funding for a three-year full time research position + running costs from the Southern and Eastern Norway Regional Health Authority for ImALPHA!
Caroline Stokke delivered an invited plenary presentation on “Dosimetry for first-in-human studies and early phase clinical trials” at the 6th Targeted Radiopharmaceutical Summit Europe.
Our group attended EANM 2024, which was held in Hamburg, Germany.
